JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$5.47B |
| 2 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$3.17B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$2.05B |
| 4 |
Amazon
AMZN
|
+$1.96B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.6B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$1.72B |
| 2 |
Vanguard Intermediate-Term Treasury ETF
VGIT
|
+$1.31B |
| 3 |
UnitedHealth
UNH
|
+$1.26B |
| 4 |
Automatic Data Processing
ADP
|
+$1.17B |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$1.08B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.17% |
| 2 | Healthcare | 10.79% |
| 3 | Financials | 9.36% |
| 4 | Consumer Discretionary | 8.67% |
| 5 | Industrials | 7.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2126
CEMIG Preferred Shares
CIG
$5.52B
| $10.8M | ﹤0.01% |
6,272,789
-966,022
| -13% | -$1.54M |
|
2127
Advanced Energy
AEIS
$13.2B
| $10.8M | ﹤0.01% |
110,062
+29,749
| +37% | +$2.8M |
|
2128
Integra LifeSciences
IART
$1.43B
| $10.8M | ﹤0.01% |
187,701
+18,452
| +11% | +$1.04M |
|
2129
NCR Voyix
VYX
$1.13B
| $10.7M | ﹤0.01% |
742,610
+53,661
| +8% | +$824K |
|
2130
Axsome Therapeutics
AXSM
$11.2B
| $10.7M | ﹤0.01% |
174,156
+6,579
| +4% | +$432K |
|
2131
PJT Partners
PJT
$4.46B
| $10.7M | ﹤0.01% |
148,654
-14,031
| -9% | -$1.08M |
|
2132
DXC Technology
DXC
$1.72B
| $10.7M | ﹤0.01% |
419,619
+81,142
| +24% | +$2.21M |
|
2133
CALL
Teradyne
TER
$65.5B
| $10.7M | ﹤0.01% |
+99,600
| New | +$10.2M |
|
2134
Sabre
SABR
$900M
| $10.7M | ﹤0.01% |
2,495,109
-1,800,222
| -42% | -$10.3M |
|
2135
Heron Therapeutics
HRTX
$63.9M
| $10.7M | ﹤0.01% |
7,086,791
+332,792
| +5% | +$833K |
|
2136
Dillards
DDS
$8.76B
| $10.7M | ﹤0.01% |
34,775
+247
| +0.7% | +$87.8K |
|
2137
Fulgent Genetics
FLGT
$511M
| $10.7M | ﹤0.01% |
342,606
+4,870
| +1% | +$157K |
|
2138
DHT Holdings
DHT
$3.14B
| $10.7M | ﹤0.01% |
988,582
+76,976
| +8% | +$774K |
|
|
HTBK
2139
DELISTED
Heritage Commerce
HTBK
| $10.7M | ﹤0.01% |
1,281,506
+51,458
| +4% | +$589K |
|
2140
National Health Investors
NHI
$3.58B
| $10.7M | ﹤0.01% |
206,838
+7,128
| +4% | +$389K |
|
|
WWE
2141
DELISTED
World Wrestling Entertainment
WWE
| $10.7M | ﹤0.01% |
116,781
-2,040
| -2% | -$174K |
|
2142
Sally Beauty Holdings
SBH
$1.54B
| $10.6M | ﹤0.01% |
682,664
+29,841
| +5% | +$464K |
|
|
NEX
2143
DELISTED
NexTier Oilfield Solutions Inc.
NEX
| $10.6M | ﹤0.01% |
1,335,567
+128,909
| +11% | +$1.15M |
|
2144
Upbound Group
UPBD
$1.14B
| $10.6M | ﹤0.01% |
433,179
+4,454
| +1% | +$115K |
|
2145
Valaris
VAL
$5.95B
| $10.6M | ﹤0.01% |
163,178
+90,863
| +126% | +$6.34M |
|
2146
TripAdvisor
TRIP
$1.26B
| $10.6M | ﹤0.01% |
534,289
+326,249
| +157% | +$6.97M |
|
2147
iQIYI
IQ
$1.3B
| $10.6M | ﹤0.01% |
1,455,351
-726,384
| -33% | -$4.98M |
|
2148
Standex International
SXI
$4.01B
| $10.6M | ﹤0.01% |
86,483
+8,331
| +11% | +$948K |
|
2149
Vanguard Materials ETF
VAW
$3.07B
| $10.6M | ﹤0.01% |
59,525
+7,004
| +13% | +$1.25M |
|
2150
PUT
Coca-Cola
KO
$377B
| $10.6M | ﹤0.01% |
170,100
-189,300
| -53% | -$11.5M |
|
Similar funds
JP Morgan Chase's Q1 2023 Portfolio in Review
As of Q1 2023, JP Morgan Chase held 7,579 positions worth $821B, up 8.2% from $759B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
JP Morgan Chase's Q1 2023 filing shows 752 new, 3,315 increased, 2,057 reduced and 651 closed positions. Its largest new stake was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M. The largest sale was Eli Lilly, an estimated $1.72B.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 14% a quarter earlier, followed by Healthcare and Financials.
- JP Morgan Chase's largest Q1 2023 buy was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M.
- JP Morgan Chase added most to JPMorgan BetaBuilders Europe ETF in Q1 2023, an estimated $5.47B increase.
- JP Morgan Chase's biggest Q1 2023 reduction was Eli Lilly, cutting an estimated $1.72B.
- JP Morgan Chase fully exited IAA, Inc. Common Stock in Q1 2023, selling an estimated $155M.
- JP Morgan Chase's ten largest holdings make up 17% of its $821B portfolio in Q1 2023.
- JP Morgan Chase opened 752 new positions and closed 651 in Q1 2023.
- JP Morgan Chase's portfolio value rose 8.2% quarter-over-quarter to $821B.
Based on JP Morgan Chase's 13F filing for Q1 2023, filed 11 May 2023.